Sonocom Co.,Ltd. (TYO:7902)
892.00
-8.00 (-0.89%)
Aug 1, 2025, 2:30 PM JST
Regulus Therapeutics Balance Sheet
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Cash & Equivalents | 3,767 | 4,187 | 4,022 | 4,283 | 3,933 | Upgrade |
Short-Term Investments | 288 | 360 | 608 | 114 | 406 | Upgrade |
Cash & Short-Term Investments | 4,055 | 4,547 | 4,630 | 4,397 | 4,339 | Upgrade |
Cash Growth | -10.82% | -1.79% | 5.30% | 1.34% | -1.63% | Upgrade |
Accounts Receivable | 822 | 665 | 657 | 728 | 653 | Upgrade |
Other Receivables | - | 2 | 59 | - | - | Upgrade |
Receivables | 822 | 667 | 716 | 728 | 653 | Upgrade |
Inventory | 152 | 132 | 133 | 129 | 106 | Upgrade |
Prepaid Expenses | 29 | 15 | 6 | 5 | 7 | Upgrade |
Other Current Assets | 9 | 7 | 5 | 7 | 9 | Upgrade |
Total Current Assets | 5,067 | 5,368 | 5,490 | 5,266 | 5,114 | Upgrade |
Property, Plant & Equipment | 2,057 | 2,035 | 1,985 | 1,880 | 1,921 | Upgrade |
Long-Term Investments | 2,394 | 2,207 | 1,634 | 2,205 | 1,901 | Upgrade |
Other Intangible Assets | 6 | 9 | 16 | 19 | 28 | Upgrade |
Long-Term Deferred Tax Assets | - | - | - | 76 | 9 | Upgrade |
Other Long-Term Assets | 1 | 1 | 2 | 1 | 1 | Upgrade |
Total Assets | 9,525 | 9,620 | 9,127 | 9,447 | 8,974 | Upgrade |
Accounts Payable | 79 | 274 | 219 | 236 | 197 | Upgrade |
Accrued Expenses | 145 | 131 | 128 | 142 | 131 | Upgrade |
Short-Term Debt | - | 4 | 43 | 7 | 6 | Upgrade |
Current Income Taxes Payable | 150 | 165 | 46 | 191 | 103 | Upgrade |
Other Current Liabilities | 3 | 9 | 4 | 13 | 4 | Upgrade |
Total Current Liabilities | 377 | 583 | 440 | 589 | 441 | Upgrade |
Long-Term Deferred Tax Liabilities | 23 | 57 | 4 | - | - | Upgrade |
Other Long-Term Liabilities | 2 | 2 | 3 | 2 | 2 | Upgrade |
Total Liabilities | 615 | 841 | 648 | 1,028 | 866 | Upgrade |
Common Stock | 925 | 925 | 925 | 925 | 925 | Upgrade |
Additional Paid-In Capital | 1,410 | 1,405 | 1,405 | 1,405 | 1,405 | Upgrade |
Retained Earnings | 7,242 | 7,074 | 6,869 | 6,745 | 6,492 | Upgrade |
Treasury Stock | -872 | -889 | -889 | -825 | -825 | Upgrade |
Comprehensive Income & Other | 205 | 264 | 169 | 169 | 111 | Upgrade |
Shareholders' Equity | 8,910 | 8,779 | 8,479 | 8,419 | 8,108 | Upgrade |
Total Liabilities & Equity | 9,525 | 9,620 | 9,127 | 9,447 | 8,974 | Upgrade |
Total Debt | - | 4 | 43 | 7 | 6 | Upgrade |
Net Cash (Debt) | 4,055 | 4,543 | 4,587 | 4,390 | 4,333 | Upgrade |
Net Cash Growth | -10.74% | -0.96% | 4.49% | 1.31% | -1.61% | Upgrade |
Net Cash Per Share | 1126.26 | 1267.24 | 1260.04 | 1197.83 | 1182.28 | Upgrade |
Filing Date Shares Outstanding | 3.61 | 3.59 | 3.59 | 3.67 | 3.67 | Upgrade |
Total Common Shares Outstanding | 3.61 | 3.59 | 3.59 | 3.67 | 3.67 | Upgrade |
Working Capital | 4,690 | 4,785 | 5,050 | 4,677 | 4,673 | Upgrade |
Book Value Per Share | 2467.29 | 2446.87 | 2359.61 | 2295.35 | 2210.56 | Upgrade |
Tangible Book Value | 8,904 | 8,770 | 8,463 | 8,400 | 8,080 | Upgrade |
Tangible Book Value Per Share | 2465.63 | 2444.36 | 2355.15 | 2290.17 | 2202.92 | Upgrade |
Order Backlog | 131 | 119 | 186 | 168 | 77 | Upgrade |
Updated Feb 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.